Earnings Outlook: Pricey rare disease drug’s launch will be likely focus of Biogen earnings 0 24.04.2017 20:48 MarketWatch.com Spinraza’s price tag — up to $750,000 in the first year — has attracted criticism. Партнёры Smi24.net Все новости за 24 часа Музыкальные новости Агрегатор новостей 24СМИ
